JP2010501188A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501188A5
JP2010501188A5 JP2009525796A JP2009525796A JP2010501188A5 JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5 JP 2009525796 A JP2009525796 A JP 2009525796A JP 2009525796 A JP2009525796 A JP 2009525796A JP 2010501188 A5 JP2010501188 A5 JP 2010501188A5
Authority
JP
Japan
Prior art keywords
composition
rna molecule
interfering rna
nucleotides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/076776 external-priority patent/WO2008024983A2/en
Publication of JP2010501188A publication Critical patent/JP2010501188A/ja
Publication of JP2010501188A5 publication Critical patent/JP2010501188A5/ja
Pending legal-status Critical Current

Links

JP2009525796A 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害 Pending JP2010501188A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24
PCT/US2007/076776 WO2008024983A2 (en) 2006-08-24 2007-08-24 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions

Publications (2)

Publication Number Publication Date
JP2010501188A JP2010501188A (ja) 2010-01-21
JP2010501188A5 true JP2010501188A5 (enExample) 2010-08-12

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525796A Pending JP2010501188A (ja) 2006-08-24 2007-08-24 IOPに関連した病態の処置のためのグレムリンのRNAi媒介阻害

Country Status (11)

Country Link
US (3) US20080051361A1 (enExample)
EP (1) EP2059597A2 (enExample)
JP (1) JP2010501188A (enExample)
KR (1) KR20090042297A (enExample)
CN (2) CN102743767A (enExample)
AU (1) AU2007286545A1 (enExample)
BR (1) BRPI0715821A2 (enExample)
CA (1) CA2659464A1 (enExample)
MX (1) MX2009001896A (enExample)
WO (1) WO2008024983A2 (enExample)
ZA (1) ZA200900553B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
WO2009046059A1 (en) * 2007-10-01 2009-04-09 Alcon Research, Ltd. Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8778904B2 (en) * 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
RU2599449C1 (ru) 2011-12-15 2016-10-10 Байонир Корпорейшн Новые конъюгаты олигонуклеотидов и их применение
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법
JP6060178B2 (ja) 2012-01-05 2017-01-18 バイオニア コーポレーションBioneer Corporation 高効率のナノ粒子型二本鎖オリゴrna構造体およびその製造方法
JP5906327B2 (ja) 2012-01-18 2016-04-20 バイオニア コーポレーションBioneer Corporation 磁性ナノ粒子−SAMiRNA複合体およびその製造方法
TR201905395T4 (tr) * 2012-03-15 2019-05-21 Hyun Kee Kim Anti-gremlin-1 antikoru.
IN2015DN02699A (enExample) * 2012-09-05 2015-09-04 Sylentis Sau
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US10030243B2 (en) 2013-07-05 2018-07-24 Bioneer Corporation Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ siRNAならびに眼の状態の処置および/または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685055A (zh) * 2001-10-31 2005-10-19 爱尔康公司 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets

Similar Documents

Publication Publication Date Title
JP2010501188A5 (enExample)
RU2008130857A (ru) Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза
RU2008150324A (ru) Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний
RU2011124528A (ru) ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ
JP2008525460A5 (enExample)
Guzman‐Aranguez et al. Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy
RU2007132874A (ru) Phki-опосредованное ингибирование мишеней повышенного внутриглазного давления
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP5241718B2 (ja) HIF−1αおよびHIF−2α発現阻害物質含有医薬
US20170073681A1 (en) RNAi-Mediated Inhibition of Frizzled Related Protein-1 for Treatment of Glaucoma
JP2009533475A5 (enExample)
JP2009540011A5 (enExample)
JP2012072152A5 (enExample)
US20100305193A1 (en) Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
JP2010540564A5 (enExample)
TW200911290A (en) RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
JP2022185052A5 (enExample)
JP2013540770A5 (enExample)
JP2008533050A5 (enExample)
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的unaオリゴマー
US20150057336A1 (en) RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
JP2009533466A5 (enExample)
JP6946297B2 (ja) NRARP遺伝子の発現を阻害するためのsiRNA、並びにそのための方法及び組成物におけるそれらの使用
CN101124322A (zh) 用于治疗青光眼的血清淀粉状蛋白A的RNAi抑制
JPWO2020061528A5 (enExample)